A nasal vaccine for COVID-19 – based on technology developed at Washington University in St. Louis – is poised to enter a phase 1 clinical trial in the U.S. after an investigational new drug ...

Dynavax should take a leaf from its vaccine maker peer, Novavax, and work to monetize its CpG1018 adjuvant. Learn more about ...

OpenAI reveals a sleek rebrand featuring a refined logo, custom typeface, and cohesive design, blending human creativity with ...

Wegovy maker Novo Nordisk is not immune to tariffs U.S. President Donald Trump is threatening to levy on the European Union, ...

Novavax (NVAX) closed the most recent trading day at $8.45, moving +0.24% from the previous trading session. The stock trailed the S&P 500, which registered a daily gain of 0.72%. Meanwhile, the Dow ...

Stocks saw a massive turnaround during Monday’s volatile trading session on news of the pausing of U.S. tariffs against ...

Novavax Inc. closed 63.58% short of its 52-week high of $23.86, which the company reached on June 6th.

Novavax Inc. closed 62.24% below its 52-week high of $23.86, which the company reached on June 6th.

Nike CEO Elliott Hill told Fortune magazine Fever star Caitlin Clark visited headquarters this month to continue development ...

Walmart’s latest brand and logo update has left some social media users baffled. On Jan. 13, the company announced in a press release on its website that it was launching a “comprehensive ...

Shares of Novavax (NVAX) have gained 3.5% over the past four weeks to close the last trading session at $8.81, but there could still be a solid upside left in the stock if short-term price targets of ...

Therefore, knowing a company's potential revenue growth is crucial. For Novavax, the consensus sales estimate for the current quarter of $90.72 million indicates a year-over-year change of -68.9%.